Novo Holdings, the controlling shareholder of Danish obesity drug maker Novo Nordisk plans to invest about $35bn by 2030, Chief Executive Kasim Kutai told Reuters on Monday. Novo Holdings will invest about $5bn a year over the next five years, which could rise to $7bn a year by 2030, Kutai said.